Evolocumab Pharmacokinetics in Healthy Subjects
What You Need to Know Before You Apply
What is the purpose of this trial?
The main objective of this trial is to evaluate the pharmacokinetics of two evolocumab drug products in healthy participants.
Who Is on the Research Team?
MD
Principal Investigator
Amgen
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single subcutaneous dose of either evolocumab drug substance A or B
Follow-up
Participants are monitored for pharmacokinetics and safety after receiving the dose
What Are the Treatments Tested in This Trial?
Interventions
- Evolocumab
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Participants will receive a single SC dose of evolocumab drug substance B.
Participants will receive a single subcutaneous (SC) dose of evolocumab drug substance A.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Amgen
Lead Sponsor
Robert A. Bradway
Amgen
Chief Executive Officer since 2012
MBA from Harvard Business School
Paul Burton
Amgen
Chief Medical Officer since 2023
MD from University of London, PhD in Molecular and Cellular Biology from Imperial College London
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.